GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE287nnn/GSE287831/primaryOK200GenomicsHomo sapiensNon-coding RNA profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287831GEOGSEfalseMicroRNA signature of lymphoblasts from amyotrophic lateral sclerosis patients as potential clinical biomarkersMicroRNAs (miRNAs) are small, non-coding RNAs involved in different cellular functions that have emerged as key regulators of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). ALS is a fatal disease that lacks of not only effective treatments, but also presents delays in its diagnosis, since useful clinical biomarkers are unavailable. In recent years, high-throughput sequencing strategies have appeared to find new ALS biomarkers, to improve early diagnosis and to assess the efficacy of new treatments. Since immortalized lymphocytes obtained from peripheral blood are a suitable model to study pathological features of ALS, we use these samples with the aim of characterize the miRNAs dysregulated in ALS patients. Next-generation sequencing (NGS) was utilized in order to analyse miRNAs expression profiles in immortalized lymphocytes from healthy controls, sporadic ALS (sALS) and familial ALS with mutations in superoxide dismutase 1 (SOD1-ALS). The screening analysis of the NGS data identified a set of dysregulated miRNAs, of which we chose 9 candidates for qRT-PCR validation, identifying for the first time the possible importance of hsa-miR-6821-5p as ALS biomarker.2026/06/16GSE287831GSM8752120GSM8752121GSM8752113GSM8752124GSM8752125GSM8752114GSM8752122GSM8752123GSM8752117GSM8752118GSM8752126GSM8752115GSM8752116GSM8752127GSM875211918573287831Homo sapiens